Boundless Bio, Inc. (BOLD)

Market Cap	33.22M
Revenue (ttm)	n/a
Net Income (ttm)	-65.36M
Shares Out	22.30M
EPS (ttm)	-3.85
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,834
Open	1.480
Previous Close	1.580
Day's Range	1.480 - 1.495
52-Week Range	1.060 - 12.650
Beta	n/a
Analysts	Buy
Price Target	22.50 (+1,410.07%)
Earnings Date	May 12, 2025

About BOLD

Boundless Bio, Inc., a clinical-stage oncology company, develops cancer therapeutics to address the unmet need of patients with oncogene amplified tumors by interrogating extrachromosomal DNA. The company’s lead product candidate is ecDTx, BBI-355, an oral inhibitor of checkpoint kinase 1 that is in Phase 1/2 clinical trial in patients with oncogene amplified cancers. It develops BBI-098, a picomolar biochemical inhibition of checkpoint kinase 1 demonstrating central nervous system penetrance in preclinical models. The company offers ECHO, an e...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 28, 2024
• Employees: 64
• Stock Exchange: NASDAQ
• Ticker Symbol: BOLD
• Website: https://boundlessbio.com

Analyst Forecast

According to 3 analysts, the average rating for BOLD stock is "Buy." The 12-month stock price forecast is $22.5, which is an increase of 1,410.07% from the latest price.

Price Target

$22.5

(1,410.07% upside)

Analyst Consensus: Buy